ArticleArchives of dermatological research2024
Unveiling the skin microbial guardians and assailants in psoriasis subtypes: a Mendelian randomization study.
Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Engineered skin commensal nanogels mitigate psoriasiform inflammation through dual regulation of cutaneous flora and host immunity.Materials today. Bio · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown an association between skin microbiota and psoriasis, but the causal relationship between skin microbiota and different psoriasis subtypes remains unexplored. Our study employed the Mendelian randomization (MR) method, using summary statistics from Genome-Wide Association Studies, to investigate the causal relationships between skin microbiota and different subtypes of psoriasis. The inverse variance weighted (IVW) method served as the primary method in our MR study. The MR-Egger intercept test, Cochran's Q test, MR-PRESSO test, and leave-one-out analysis were conducted for sensitive analyses. Bayesian weighted Mendelian randomization (BWMR) method was conducted to enhance our results. For psoriasis vulgaris, our results showed that asv016 [Enhydrobacter (unc.)], alphaproteobacteria, and asv070 [Veillonella (unc.)] may serve as protective factors. Meanwhile, asv009 [D. nitroreducens], asv010 [Staphylococcus (unc.)], Neisseriaceae, and clostridiales were found to be risk factors. For guttate psoriasis, our findings suggested that asv023 [C. kroppenstedtii], asv039 [Acinetobacter (unc.)], bacteroidales, paracoccus, and betaproteobacteria may serve as protective factors, while asv008 [Staphylococcus (unc.)], asv061 [S. mitis], asv086 [A. johnsonii], finegoldia, and flavobacteriaceae emerged as potential risk factors. For generalized pustular psoriasis, our findings identified asv039 [Acinetobacter (unc.)], asv009 [D. nitroreducens], and Staphylococcus as potential protective factors, whereas asv016 [Enhydrobacter (unc.)], asv006 [S. hominis], bacteroidales, and bacteroides emerged as potential risk factors. For psoriatic arthropathies, our findings suggested that Propionibacterium, asv053 [Streptococcus (unc.)], asv093 [Staphylococcus (unc.)], rothia may serve as protective factors, while asv012 [S. hominis], corynebacterium, clostridiales, flavobacteriaceae, anaerococcus, asv013 [S. epidermidis] were associated with increased risk. Our findings suggest potential causal relationships between certain skin microbiota and different subtypes of psoriasis, highlighting their potential as novel biomarkers for diagnosing different subtypes of psoriasis, and offering promising avenues for developing microbiome-based diagnostics and targeted therapies for diverse psoriasis subtypes.
Indexed as
Identifiers
39656273What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.